Results 71 to 80 of about 780 (156)

Allograft function predicts mortality in kidney transplant recipients with severe COVID-19: a paradoxical risk factor [PDF]

IntroductionKidney transplant recipients (KTRs) are at a higher risk of severe coronavirus disease (COVID-19) because of their immunocompromised status. However, the effect of allograft function on the prognosis of severe COVID-19 in KTRs is unclear.
Han Luo, Han Luo, Hongji Yang, Hongji Yang, Hongji Yang, Jingyu Wen, Qing Ran, Qing Ran, Yifu Hou, Yifu Hou   +9 more
core   +1 more source

Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy

Journal of Medical Virology, Volume 97, Issue 5, May 2025.
ABSTRACT Nirmatrelvir‐ritonavir (NMV‐r) has been widely used to treat coronavirus disease 2019 (COVID‐19) for a standard period of 5‐days. However, there are increasing reports of patients with persistent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) positivity after the standard 5‐day course of NMV‐r treatment.
Huqin Yang, Leyi Gao, Yi Xue, Zhijin Zhang, Lujia Guan, Haifan Zhang, Haomiao Ma, Xuyan Li, Jieqiong Li, Zhaohui Tong   +9 more
wiley   +1 more source

LONG-TERM IMMUNOLOGICAL CONSEQUENCES OF COVID-19 ON HEALTH [PDF]

, 2022
SARS-Cov-2 (severe acute respiratory syndrome coronavirus) that initially came to notice in December 2019 is the agent responsible for COVID-19 is still spreading rapidly worldwide and it is presently a potent danger to the world and also to the economy.
AHER, PRAJWAL, AVHAD, RUPALI, BAJAIT, MANOJ, GADE, NIKHIL, JADHAV, ANIL, KADAM, HARSHADA, KAPHARE, GAURI, TALELE, SWATI   +7 more
core   +1 more source

Clinical characteristics and prognosis of SARS-CoV-2 infection in lung transplant recipients [PDF]

ObjectiveThis study aimed to investigate the clinical manifestations and prognosis of lung transplant (LTx) recipients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the coronavirus disease (COVID-19) pandemic ...
Li Wei, Qiangming Li, Shuai Hu, Tian Xia, Wenping Zhang, Zeheng Ma, Zhijun Han, Zibo Zhu   +7 more
core   +1 more source

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This is the first study comparing the effectiveness of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in treating moderate and severe COVID‐19 patients. Patients who received simnotrelvir/ritonavir exhibited shorter hospitalization. Disease progression, viral clearance times, and symptom resolution time were similar between the two groups.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
wiley   +1 more source

Fuzheng Jiedu granules against disease progression among high-risk adults with non-severe COVID-19: a multicenter retrospective cohort study [PDF]

BackgroundFuzheng Jiedu (FZJD) granules are widely used to treat coronavirus disease (COVID-19) since their market approval, but their clinical effectiveness remains uncertain.
Bo Yu, Danwen Zheng, Danwen Zheng, Danwen Zheng, Hailang He, Hanhong Zhang, Jingwei Shui, Longde Wang, Qiaoli Hua, Qing Liu, Qing Liu, Qing Liu, Qiumin Chen, Rongyuan Yang, Rongyuan Yang, Rongyuan Yang, Shengle Qin, Tong Zhang, Tong Zhang, Weng Heng, Xiaohua Xu, Xiaohua Xu, Xinghua Tan, Yang Yang, Yihang Cai, Yihang Cai, Yuntao Liu, Yuntao Liu, Yuntao Liu, Zhongde Zhang, Zhongde Zhang, Zhongde Zhang   +31 more
core   +1 more source

Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis

PLOS ONE
Objective The aim of this study was to assess the effectiveness and safety of azvudine in treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Methods A search was carried out in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until October 20, 2023.
Bahman Amani, Behnam Amani
openaire   +2 more sources

Coronavirus disease-19 : an interim evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid) [PDF]

, 2020
Coronavirus disease 2019 (COVID-19) is a rapidly evolving, highly transmissible, and potentially lethal pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of June 11 2020, more than 7,000,000 COVID-19
Abu-Raya, Bahaa, Esposito, Susanna, Silva, Denise Rossato   +2 more
core  

Cover Picture: Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study (View 2/2025)

VIEW, Volume 6, Issue 2, April 2025.
In the cohort of SARS‐CoV‐2 infected patients with pre‐existing chronic respiratory diseases, azvudine can not only relieve disease symptoms by blocking the activity of the viral RNA polymeraseand inhibiting viral replication, but also perform immune‐enhancing effect by increasing the number and function of serum lymphocytes, and thus activating the ...
Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu, Guowu Qian, Yiqiang Yuan, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yanyang Zhang, Xinjun Hu, Zujiang Yu, Guangying Cui, Zhigang Ren   +17 more
wiley   +1 more source

Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study. [PDF]

Front Cell Infect Microbiol
BackgroundAzvudine (AZV), the first Chinese oral anti-coronavirus disease 2019 (COVID-19) drug, has shown substantial clinical benefits to viral clearance and prognosis in patients with mild and common COVID-19. However, there is no evidence in severe hospitalized COVID-19 patients.MethodsIn this multicenter study, we analyzed 209 severe hospitalized ...
Zhang ML, Wei XY, Su N, Jiang JH, Xu GP, Zeng DX.   +5 more
europepmc   +4 more sources